Silencing of Carbohydrate Sulfotransferase 15 Hinders Murine Pulmonary Fibrosis Development
2017 · Molecular Therapy — Nucleic Acids · 34 citations
https://doi.org/10.1016/j.omtn.2016.12.008
Y
Yoshiro Kai
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
32
Papers
231
Citations
9
h-index
8
i10-index
Yoshiro Kai is an academic researcher from Nara Medical University. The author has contributed to research in topics: Asthma and respiratory diseases & Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Sinusitis and nasal conditions. The author has an h-index of 9, co-authored 28 publications.
ORCID: 0000-0001-6197-5176Papers by this author
worksA case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy
2022 · Respiratory Medicine Case Reports · 9 citations
https://doi.org/10.1016/j.rmcr.2022.101794
Lung cancer resembling allergic bronchopulmonary mycosis with an asthma-like presentation
2023 · Respiratory Medicine Case Reports · 4 citations
https://doi.org/10.1016/j.rmcr.2023.101887
Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series
2024 · Journal of Allergy and Clinical Immunology Global · 3 citations
https://doi.org/10.1016/j.jacig.2024.100396
Dupilumab treatment and 3-dimensional bronchial tree changes in asthma-COPD overlap
2025 · Journal of Allergy and Clinical Immunology Global · 1 citations
https://doi.org/10.1016/j.jacig.2025.100530
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat